share_log

HOOKIPA Pharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Invus Public Equities, L.P.(5.9%),Invus Public Equities Advisors, LLC(5.9%), etc.

HOOKIPA Pharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Invus Public Equities, L.P.(5.9%),Invus Public Equities Advisors, LLC(5.9%), etc.

HOOKIPA Pharma | SC 13G/A：超過5%持股股東披露文件(修正)-Invus Public Equities, L.P.(5.9%),Invus Public Equities Advisors, LLC(5.9%)等
美股SEC公告 ·  08/03 06:40
牛牛AI助理已提取核心訊息
On July 25, 2024, a significant reorganization took place affecting the ownership structure of HOOKIPA Pharma Inc. Invus Global Management, LLC became the managing member of Invus Public Equities Advisors, LLC, resulting in a shift in beneficial ownership of HOOKIPA Pharma's common stock. Invus Public Equities, L.P. now directly holds 566,640 shares, representing 5.9% of the company, with Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., and Mr. Raymond Debbane potentially deemed to beneficially own these shares due to their respective control relationships. This change follows the exit of the Artal Parties, including Artal International, Artal International Management, Artal Group, Westend, Stichting Administratiekantoor Westend, and Mr. Amaury Wittouck, who are no longer considered beneficial owners of the shares previously held by Invus Public Equities. The reorganization was reported in a Schedule 13G filing with the SEC, reflecting the updated ownership status immediately following the event.
On July 25, 2024, a significant reorganization took place affecting the ownership structure of HOOKIPA Pharma Inc. Invus Global Management, LLC became the managing member of Invus Public Equities Advisors, LLC, resulting in a shift in beneficial ownership of HOOKIPA Pharma's common stock. Invus Public Equities, L.P. now directly holds 566,640 shares, representing 5.9% of the company, with Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., and Mr. Raymond Debbane potentially deemed to beneficially own these shares due to their respective control relationships. This change follows the exit of the Artal Parties, including Artal International, Artal International Management, Artal Group, Westend, Stichting Administratiekantoor Westend, and Mr. Amaury Wittouck, who are no longer considered beneficial owners of the shares previously held by Invus Public Equities. The reorganization was reported in a Schedule 13G filing with the SEC, reflecting the updated ownership status immediately following the event.
2024年7月25日，HOOKIPA Pharma Inc的所有權結構發生了重大變革。Invus Global Management，LLC成爲Invus Public Equities Advisors，LLC的管理會員，進而導致HOOKIPA Pharma普通股的受益所有權發生轉移。Invus Public Equities，L.P. 直接持有566,640股股票，代表公司的5.9％，因各自的控制關係，可能被認爲是Invus Public Equities Advisors，LLC，Invus Global Management，LLC，Siren，L.L.C.和Mr. Raymond D...展開全部
2024年7月25日，HOOKIPA Pharma Inc的所有權結構發生了重大變革。Invus Global Management，LLC成爲Invus Public Equities Advisors，LLC的管理會員，進而導致HOOKIPA Pharma普通股的受益所有權發生轉移。Invus Public Equities，L.P. 直接持有566,640股股票，代表公司的5.9％，因各自的控制關係，可能被認爲是Invus Public Equities Advisors，LLC，Invus Global Management，LLC，Siren，L.L.C.和Mr. Raymond Debbane的受益所有權。此次變更是Artal Parties（包括Artal International，Artal International Management，Artal Group，Westend，Stichting Administratiekantoor Westend和Mr. Amaury Wittouck）退出後發生的，他們不再被認爲是Invus Public Equities之前持有的股份的受益所有者。該重組已在提交給SEC的13G表格中報告，反映了事件發生後更新的所有權狀態。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。